Ra Pharmaceuticals, Inc. (RARX) EPS Estimated At $-0.57 on May, 10

May 3, 2018 - By Ira Colvard

On May, 10. Investors wait Ra Pharmaceuticals, Inc. (NASDAQ:RARX) to reveal its quarterly earnings, according to Faxor. Analysts predict $-0.57 earnings per share, which is $0.07 down or 14.00 % from 2017’s $-0.5 earnings per share. Analysts at Wall Street see Ra Pharmaceuticals, Inc.’s -14.93 % EPS growth compared to $-0.67 earnings per share for last quarter. RARX is touching $5.96 during the last trading session, after decreased 3.52%.Currently Ra Pharmaceuticals, Inc. is downtrending after 74.40% change in last May 3, 2017. RARX has also 24,974 shares volume. RARX underperformed the S&P500 by 85.95%.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States.The company has $192.50 million market cap. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.Currently it has negative earnings. The Company’s lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria , as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP).

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: